Orexigen Therapeutics is a biopharmaceutical company focuses on the development of pharmaceutical product candidates for the treatment of obesity. The Company's product, Contrave, is approved in the United States by the United States Food and Drug Administration as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adults. Contrave is a prescription medicine that contains 2 medicines (naltrexone HCl and bupropion HCl) that may help some obese adults, or overweight adults who also have weight-related medical problems, lose weight and keep the weight off.

Type
Public
HQ
San Diego, US
Founded
2002
Size (employees)
132 (est)
Orexigen Therapeutics was founded in 2002 and is headquartered in San Diego, US
Report incorrect company information

Orexigen Therapeutics Office Locations

Orexigen Therapeutics has an office in San Diego
San Diego, US (HQ)
200 3344 N Torrey Pines Ct
Show all (1)
Report incorrect company information

Orexigen Therapeutics Financials and Metrics

Orexigen Therapeutics Financials

Orexigen Therapeutics's revenue was reported to be $33.71 m in FY, 2016 which is a 37.8% increase from the previous period.
USD

Revenue (Q3, 2017)

18.9 m

Gross profit (Q3, 2017)

14.9 m

Gross profit margin (Q3, 2017), %

78.6%

Net income (Q3, 2017)

(120.4 m)

EBIT (Q3, 2017)

(22.8 m)

Market capitalization (3-Apr-2018)

3.4 m

Cash (30-Sep-2017)

45.6 m
Orexigen Therapeutics's current market capitalization is $3.4 m.
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016

Revenue

3.4 m55.5 m24.5 m33.7 m

Revenue growth, %

1520%(56%)38%

Cost of goods sold

8 m

Gross profit

25.7 m
Quarterly
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017

Revenue

857 k857 k857 k30.9 m4.4 m5.2 m10 m5 m7.8 m7 m19.1 m23.4 m18.9 m

Cost of goods sold

1.8 m1.9 m6.2 m6.8 m4 m

Gross profit

6 m5.1 m13 m16.5 m14.9 m

Gross profit Margin, %

77%72%68%71%79%
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016

Cash

98.1 m104.2 m155.4 m92.5 m

Accounts Receivable

2.6 m6.8 m1.1 m

Inventories

1.3 m1.5 m2.3 m23.2 m

Current Assets

178.3 m211.3 m233.9 m224.5 m
Quarterly
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017

Cash

48.7 m37.6 m31.1 m68.4 m75.1 m71.6 m154.3 m68 m78.2 m74.4 m76.7 m36.7 m45.6 m

Accounts Receivable

32 m4.5 m6.8 m4.6 m2.8 m2.9 m2.1 m6.3 m7.6 m19.1 m

Inventories

754 k1.4 m4.9 m11.1 m15 m11.5 m24 m20.7 m15.8 m16.1 m

Current Assets

84.6 m156.4 m139.1 m153.2 m196.4 m189.3 m251.8 m262.4 m282.7 m273.2 m158.5 m114.3 m112.3 m
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016

Net Income

(77.7 m)(37.5 m)(68.7 m)(24.5 m)

Depreciation and Amortization

94 k139 k223 k3.7 m

Inventories

205 k(175 k)(781 k)1.5 m

Accounts Payable

(2.3 m)2.1 m1 m11.8 m
Quarterly
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

Net Income

(56.2 m)(24.9 m)(49.4 m)(38.1 m)(17.2 m)(39.7 m)(50.9 m)(22.3 m)(47.6 m)85 k(69.1 m)

Depreciation and Amortization

84 k8 k46 k87 k51 k103 k157 k78 k194 k1.7 m

Inventories

(754 k)(158 k)(3.7 m)(9.8 m)(4.1 m)(596 k)618 k20.7 m

Accounts Payable

(4.2 m)(1.2 m)1.7 m(1.1 m)(3.8 m)6.9 m4 m(1.9 m)2.5 m13.1 m15.6 m
USDY, 2017

Revenue/Employee

143.2 k

Financial Leverage

-2.9 x
Show all financial metrics
Report incorrect company information